Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research
Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.
Pharma & Biotech
Pharma & Biotech
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.